A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
- 15 September 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (611) , eaba7791
Abstract
TAK-981, a first-in-class small-molecule SUMOylation inhibitor, activates type I interferon signaling to promote antitumor immune responses in mice.Keywords
This publication has 54 references indexed in Scilit:
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- Timing and Magnitude of Type I Interferon Responses by Distinct Sensors Impact CD8 T Cell Exhaustion and Chronic Viral InfectionCell Host & Microbe, 2012
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsJournal of Experimental Medicine, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- Inflammatory signaling compromises cell responses to interferon alphaOncogene, 2011
- Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and InterpretationPLOS ONE, 2010
- Complete but curtailed T-cell response to very low-affinity antigenNature, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15Immunity, 2007
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003